Dr. Perlman serves as an advisor to Acelot. He has been a long-time leader in the biotechnology field, and currently serves as Co-Founder and Head of Pre-Clinical Science at X-37, an AI-enabled drug discovery company, as well as Co-Founder and Chief Medical Officer at Velocity Pharmaceutical Development. Dr. Perlman has an impressive track record of successfully working in innovative and intensely competitive drug discovery and development organizations, including in the field of oncology and immuno-oncology. He also served as CEO of Affymax, Executive Vice President at Tularik Inc. and was the Senior Director of Clinical Research at Genentech. At Genentech, he greatly contributed to their early success, evident through his large role in the development, FDA approval and marketing of the human growth hormone, Nutropin.

Dr. Perlman holds an MD and PhD from New York University, and a BS degree in Physics from the Massachusetts Institute of Technology.